Effect of Paricalcitol Over Vessel Wall

Effect of Paricalcitol Over Vessel Wall: Pleiotropic Analogues Vitamin D Effects

To provide evidence based prospectives of the potential benefit effects of paricalcitol, an analog of vitamin D, over the prevention / retardation of the progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.

Providing prospective results based on evidence of potential beneficial effects of paricalcitol, an analogue of vitamin D in the prevention / delay of progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.

Inclusion Criteria:

• Patients aged between 50 and 75 years.
• Chronic kidney disease stage 5 D or 4-5 No D as calculated glomerular filtration rate (MDRD).
• Concentration of intact parathyroid hormone (iPTH): 150-400 pg/ml.
• Plasma concentrations of 25 (OH) vitamin D <30 ng/ml.
• Without vitamin D supplementation for 3 months before the study.
• Serum P> 3.8 mg / dl.
• Serum Ca> 9.8 mg / dl.
• No history of cardiovascular events (angina or myocardial infarction, stroke, peripheral arterial disease).
• No exclusion criteria for the use of contrast.

Exclusion Criteria:

• Allergic reaction to sulfur hexafluoride.
• Recent unstable cardiac symptoms.
• Patients with recent coronary intervention (<7 days)
• Patients with class III and IV heart failure or severe arrhythmias.
• Severe pulmonary hypertension.